Results 21 to 30 of about 35,440 (172)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion.
Jeannine Witte, Melanie Mühlbauer, Diana Braun, Antje Steinbach, Janine Golchert, Rainer Rettig, Olaf Grisk   +6 more
doaj   +1 more source

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence

Breast Cancer Research, 2020
Background Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006.
Denian Wang, Fei Xiao, Zhongxue Feng, Min Li, Lingmiao Kong, Luping Huang, Yong’gang Wei, Hongyu Li, Fei Liu, Haili Zhang, Wei Zhang   +10 more
doaj   +1 more source

Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma

Scientific Reports, 2022
Sunitinib, a VEGF blockade, is used to treat clear cell renal cell carcinoma (ccRCC). However, the anti-cancer treatment effects of sunitinib do not last long in ccRCC patients.
Hyun Ji Hwang, Seong Hwi Hong, Hong Sang Moon, Young Eun Yoon, Sung Yul Park   +4 more
doaj   +1 more source

Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma

Cancer Treatment and Research Communications, 2021
Brain metastases from renal cell carcinoma are associated with poor prognosis. Sunitinib is a multi-targeted tyrosine kinase inhibitor used for the treatment of metastatic renal cell carcinoma.
Mali Amirault, Sylvia Choo, Timothy Waxweiler, Sarah D. Weisdack, Kathryn Breaker, Thomas W. Flaig, Elaine T. Lam   +6 more
doaj   +1 more source

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study

Translational Oncology, 2014
AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities.
Yen-Yang Chen, Chun-Nan Yeh, Chi-Tung Cheng, Chao-En Wu, Kun-Chun Chiang, Tsung-Wen Chen, Chih-Chi Wang, Jen-Shi Chen, Ta-Sen Yeh   +8 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model

JACC: Basic to Translational Science, 2018
Summary: Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors, results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated individuals.
Rachel Truitt, PhD, Anbin Mu, Elise A. Corbin, PhD, Alexia Vite, PhD, Jeffrey Brandimarto, PhD, Bonnie Ky, MD, MSCE, Kenneth B. Margulies, MD   +6 more
doaj   +1 more source

Targeting WDR12 Unleashes T‐Cell‐Mediated Antitumor Activity in Melanoma by Destabilizing CD276

Advanced Science, EarlyView.
WDR12 cooperates with the chaperonin subunit CCT7 to maintain CD276 stability on tumor cells, suppressing T‐cell activity and promoting immune escape. SU14813, a small‐molecule WDR12 inhibitor, reduces CD276 stability and relieves CD276‐mediated T‐cell suppression.
Jie Pan, Ruimin Chang, Meng Zhang, Qian Dong, Guanxiong Zhang, Xiang Chen, Mingliang Chen, Lixia Lu, Xiaowei Liang, Yeye Guo, Juan Su   +10 more
wiley   +1 more source

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

Journal of Experimental & Clinical Cancer Research, 2020
Background Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment ...
Ninadh M. D’Costa, Matthew R. Lowerison, Peter A. Raven, Zheng Tan, Morgan E. Roberts, Raunak Shrestha, Matthew W. Urban, Cesar U. Monjaras-Avila, Htoo Zarni Oo, Antonio Hurtado-Coll, Claudia Chavez-Munoz, Alan I. So   +11 more
doaj   +1 more source

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. [PDF]

PLoS ONE, 2012
Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su ...
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A Schwarz, Roderich E Schwarz   +4 more
doaj   +1 more source